

Roll No

--	--	--	--	--

Institute of Teaching and Research in Ayurveda

Ph.D. Entrance Examination - 2025

(3rd May 2025)

Paper - II

Subject

Kayachikitsa



**For admission in
Ayurvedyavaridhi (Ph.D.-Ayurveda)**

**Conducted by:
Institute of Teaching and Research in Ayurveda
Jamnagar - 361008
Gujarat, India**

Note:

1. Candidates are instructed to **NOT TO OPEN** the question booklet till said to do so.
2. Candidates are advised to read the instructions provided at last page of this question booklet carefully, before answering the questions.

37

Kayachikitsa

- Which of these are characteristics of *Kaphaja Jwara* as per Sushruta Samhita?
 - बद्धवितृकता, जृम्भा, आध्मान
 - गौरवं, रोमहर्ष, कास
 - वमिः, प्रलापः, वेगस्तीक्ष्णोऽतिसार
 - जृम्भा, रुगल्पत्वं, स्तम्भो गात्राणां
- Fill in the blanks(As per Sushruta): सन्यस्तगात्रं ----- विद्यात् सर्वात्मके ज्वरे।
 - सन्निपात
 - ओजोनरोधजं
 - सन्यासं
 - अभिघातज
- What is to be administered to the patient of *Atisara* if he presents with - स्तोकं स्तोकं विबद्धं वा सशूलं -as per Sushruta?
 - Abhaya Pippali Kalka* (अभया पिप्पली कल्क)
 - Ushnodaka* (उष्णोदक)
 - Vamana* (वमन)
 - Pathya* (पथ्य)
- Which of these is **NOT** indicated for *Kshaya Rogi* (क्षय रोगी) as per Sushruta?
 - Rasona Yoga* (रसोन योग)
 - Bala Prayoga* (बला प्रयोग)
 - Nagabala Prayoga* (नागबला प्रयोग)
 - Magdhika Prayoga* (मागधिक प्रयोग)
- Torsades de pointes is complication of -----
 - Prolonged ventricular repolarisation
 - Diffused atrium depolarisation
 - Prolonged ventricular depolarisation
 - Short ventricular repolarisation
- Match the following as per the *Ashtanga Hridaya* in relation to *Gatavata* (गत वात) and its treatment

(a) कोष्ठगते वाते	(i) स्वेदन, अभ्यङ्ग
(b) मांस गते वाते	(ii) क्षार चूर्ण, दीपन, पाचन
(c) त्वग् गते वाते	(iii) स्नेह, दाह, उपनाह
(d) सिरागते वाते	(iv) विरेचन, निरुह
(A) a-iv, b-i, c-iii, d-ii	(B) a-ii, b-iii, c-iv, d-i
(C) a-ii, b-iv, c-i, d-iii	(D) a-i, b-iv, c-iii, d-ii
- What is to be added in *Eranda Taila*, if *Vata Gulma* is associated with *Shleshma* as per *Ashtanga Hridaya*?
 - Sidhu* (सिधु)
 - Prasanna* (प्रसन्ना)
 - Payasa* (पयस)
 - Tila Taila* (तिल तैल)
- Which among these is **NOT** the *Updarava* of *Visuchika* (विसूचिका) as per Bhavaprakasha?
 - Kampa* (कम्प)
 - Arati* (अरति)
 - Mutraghata* (मूत्राघात)
 - Pipasa* (पिपासा)

Kayachikitsa

9. Medicated water of which of these can be given in the management of *Atisara* (अतिसार) as per Bhaishajya Ratnawali?
- (A) शृङ्गवेर, हीबेर (B) पिप्पली, गुडूची
(C) नागर, चित्रक (D) शृङ्गवेर, चन्दन
10. What is the indication of *Khanda Kushmanada* (खण्ड कुष्माण्ड) as per Bhavaprakasha?
- (A) *Kshina Shukra* (क्षीण शुक्र) (B) *Grahani* (ग्रहणी)
(C) *Amlapitta* (अम्लपित्त) (D) *Anidra* (अनिद्रा)
11. Fill in the blanks as per Bhavaprakasha : यत्र नान्ने भवेत् श्रद्धा सो ----- उच्यते
- (A) अरोचक (B) भक्त द्वेष
(C) अजीर्ण (D) अभक्च्छन्दम्
12. *Pashupato Rasa* (पाशुपतो रस) has been mentioned as indication of which of these following as per Bhaishajya Ratnawali?
- (A) *Visuchika* (विसूचिका) (B) *Pandu* (पाण्डु)
(C) *Jvara* (ज्वर) (D) *Raktapitta* (रक्तपित्त)
13. *Dadimadya Ghrita* (दडिमाद्य घृत) mentioned in Charaka Samhita in context of *Pandu Roga Chikitsa* is also indicated in -----
- (A) *Hridroga, Mudavata, Shwasa* (हृदरोग, मूढवात, श्वास)
(B) *Jvara, Daha, Grahani* (ज्वर, दाह, ग्रहणी)
(C) *Arsha, Raktapitta, Jvara* (अर्श, रक्तपित्त, ज्वर)
(D) *Visphota, Jvara, Unmada* (विस्फोट, ज्वर, उन्माद)
14. Which of these is indicated as *Prayoga* (प्रयोग) for *Kshata Ksheena* (क्षतक्षीण) as per Charaka?
- (A) मण्डूकपर्णी, अश्वगन्धा, बला (B) नागबला, शुण्ठी, मण्डूकपर्णी
(C) यष्टिमधु, अश्वगन्धा, बला (D) शतावरी, मण्डूकपर्णी, नागबला
15. Which statement is true in regards of *Guda* (गुड) and *Nagara* (नागर) *Prayoga* (प्रयोग) in the management of *Shotha* (शोथ) as per Charaka?
- (A) *Guda* and *Nagara* shall be taken in ratio of 2:1 and to be increased by *Ardha Pala* daily
(B) *Guda* and *Nagara* shall be taken in equal quantity and to be increased by one *Pala* daily
(C) *Guda* and *Nagara* shall be taken in equal quantity and to be increased by *Ardha Pala* daily
(D) *Nagara* shall be taken in $\frac{1}{4}$ of the *Guda* and to be increased by one *Pala* daily
16. शरीरानुगते सामे रसे लङ्घनपाचनम् is mentioned in context of ----- as per Charaka?
- (A) *Rajyakshma* (राजयक्ष्मा) (B) *Atisara* (अतिसार)
(C) *Grahani* (ग्रहणी) (D) *Grahani* and *Atisara* (ग्रहणी एवं अतिसार)

Kayachikitsa

17. Match the following for *Anupana* of *Yogarajguggulu* (योगराज गुग्गुलु) for the following diseases as per Bhavaprakasha.

- | | |
|-----------------------------|-----------------------------|
| (a) पाण्डु | (i) निम्ब क्वाथ |
| (b) कुष्ठ | (ii) दावी क्वाथ |
| (c) मेह | (iii) पुनर्नवादि क्वाथ |
| (d) उदररोग | (iv) गोमूत्र |
| (A) a-ii, b-i, c-iv, d -iii | (B) a-iv, b-i, c-ii, d- iii |
| (C) a-iii, b-i, c-ii, d iv | (D) a-iii, b-iv, c-ii, d- i |

18. तदेव तरुणे पीतम् विषवत् हन्ति मानवं----This statement has been mentioned by Sushruta in context of *Jvara* for which of the following ?

- | | |
|-------------------------|---------------------------|
| (A) <i>Ghrita</i> (घृत) | (B) <i>Payasa</i> (पयस) |
| (C) <i>Takra</i> (तक्र) | (D) <i>Kashaya</i> (कषाय) |

19. पार्श्वे तस्य अवगृह्णाति शयानस्य समीरणः is mentioned in context of ----- by Charaka

- | | |
|----------------|-------------------|
| (A) क्षत क्षीण | (B) संग्रह ग्रहणी |
| (C) तमक श्वास | (D) पार्श्व शूल |

20. What are the indications of *Navayasa Lauha* (नवायास लौह) as per Bhaishajya Ratnawali?

- | | |
|------------------------------|-------------------------|
| (A) हृद्रोग, स्थौल्य, अर्श | (B) पाण्डु, कामला, अर्श |
| (C) पाण्डु, स्थौल्य, हृद्रोग | (D) कामला, ज्वर, ग्रहणी |

21. उदावर्तहरं कर्म कार्यं वातघ्नं एव च- ---- is related to which of the following as per Charaka?

- | | |
|-----------------|-------------------|
| (A) निरुह बस्ति | (B) वातोदर |
| (C) बद्धोदर | (D) पक्वाशयगत वात |

22. What can be given in the case, when the *Chhardiroga* (छर्दि रोग) has become chronic as per Charaka?

- | | |
|----------------------------------|---|
| (A) <i>Sarpiguda</i> (सर्पि गुड) | (B) <i>Harshana</i> (हर्षण) |
| (C) <i>Ikshurasa</i> (इक्षुरस) | (D) <i>Tandula Dhavana</i> (तण्डुलधावन) |

23. Which of these *Rasayana* is **NOT** mentioned by Charaka for the treatment of *Kaphaja Hridroga* (कफज हृद्रोग)?

- | | |
|--|--|
| (A) <i>Shilajatu Kalpa</i> (शिलाजतु कल्प) | (B) <i>Triphala Prayoga</i> (त्रिफला प्रयोग) |
| (C) <i>Agatsya Haritaki Avaleha</i> (अगत्स्य हरीतकी) | (D) <i>Brahma Rasayana</i> (ब्रह्म रसायन) |

24. Which of these statements is true in regards of *Chandramrita Rasa* (चन्द्रामृत रस) mentioned as per Bhaishajya Ratnawali?

- | | |
|--|--------------------------------|
| (a) बलवर्णकरो ह्येष प्लीहा गुल्म उदरपाहः | (b) हन्ति पञ्च विध कासं |
| (c) कासिनां मेध्यं हृद्य रसायनं | (d) रक्तनिष्ठिविनाश्चापि ज्वरं |
| (A) Only b | (B) Only c and d |
| (C) a, c and d | (D) a, b and d |

Kayachikitsa

25. Which of these is an example of Nucleoside Reverse Transcriptase Inhibitors (NRTIS)?
 (A) Atazanovir (B) Dolutegravir
 (C) Tenofovir (D) Efavirenz
26. Which of these is **NOT** the characteristic of *Visarpa* as per Sushruta ?
 (A) उन्नतं शोफ (B) अनुन्नतं शोफ
 (C) विस्तृत शोफ (D) सर्वतो विसरणात्
27. Fill in the blanks: ----- घृतं ह्येतत् कफ व्याधि निसुदनम् (as per Charaka)
 (A) कण्टकारी (B) त्रिफला
 (C) कुलत्थादि (D) पिप्पली
28. Fill in the blanks: एतत् प्रायोगिकं सर्पिः----- इति स्मृतं वातरक्ते क्षतेक्षीणे विसर्पे पैत्तिके ज्वरे (as per Charaka)
 (A) वासा (B) बलादि
 (C) स्थिरादि (D) पारुषकं
29. त्वग्गतमेव ----- अपरिस्रावि - Complete the verse as per Sushruta
 (A) काकणं (B) विचर्चिका
 (C) किलासं (D) विपादिकां
30. Which of these is the indication of अष्टकट्वर तैल as per Charaka Samhita?
 (A) वातरक्त (B) गृध्रसी
 (C) उरुग्रह (D) Both B and C
31. What is to be used for the management of घ्राणप्रवृत्त रक्तपित्त for the purpose of *Nasya* as per Sushruta Samhita?
 (A) द्राक्षा रस (B) अजा रक्त
 (C) रसाञ्जन (D) पद्मक स्वरस
32. What are the indications of *Vatari Guggulu* (वातारि गुग्गुलु) mentioned in *Amavata* (आमवात) chapter of Bhaishjya Ratnawali?
 (A) गृध्रसी, वात रक्त, क्रोष्टृकशीर्ष (B) गृध्रसी, वातभग्न, दुष्टव्रण
 (C) गृध्रसी, कास, श्वास (D) गृध्रसी, कटिगत वात, उन्माद
33. करोत्यावृत्त मार्गत्वात् रसादिश्च उपशोषयेत is mentioned in context of ----- as per Charaka?
 (A) राजयक्ष्मा (B) वातव्याधि
 (C) तमकश्वास (D) पाण्डु
34. What are the indications of महाकल्याणक घृत mentioned in *Unmada* (उन्माद) chapter of Sushruta Samhita?
 (A) शोष, अभीजताम, अपस्मार (B) ग्रहणी, गुल्म, क्षय
 (C) क्षय, अनिद्रा, अरुचि (D) ज्वर, अरुचि, उन्माद

Kayachikitsa


35. What is to be used as *Anupana* of *Shilajatu*, *Guggulu*, *Pippali*, *Nagara*, mentioned for the treatment of *Urustambha* as per Bhaishjya Ratnawali?
- (A) *Gomutra* (गोमूत्र) (B) *Triphala Kwatha* (त्रिफला क्वाथ)
 (C) *Guduchi Swarasa* (गुडूची स्वरस) (D) *Panchabhadra Kwatha* (पञ्चभद्र क्वाथ)
36. Which of these *Patra* is mentioned in the preparation of *Patra Lavana* (पत्र लवण) in the treatment of *Vata Roga* as per Sushruta?
- (A) *Gandharva Hasta* (गन्धर्व हस्त) (B) *Gandira* (गण्डीर)
 (C) *Kutaja* (कुटज) (D) *Paribhadra* (पारिभद्र)
37. *Guda Haritaki* (गुडहरीतकी) is mentioned in the treatment of ----- *Vatarakta* (वातरक्त) as per Sushruta?
- (A) *Kapha Pradhana* (कफ प्रधान) (B) *Kapha Pradhana and Rakta Pradhana* (कफ प्रधान एवं रक्त प्रधान)
 (C) *Rakta Pradhana* (रक्त प्रधान) (D) *Vata Pradhana* (वात प्रधान)
38. Which of these is **NOT** an example of immune therapy?
- (A) Tumor Infiltrating Lymphocyte (TIL) therapy (B) Engineered T Cell therapy (TCR)
 (C) Chimeric Antigen Receptor T cell (CAR-T) therapy (D) Chemotherapy
39. ----- recognizes good prescribing in old age that ensure effective treatments are prioritized as well as discontinue those medications that may be of limited benefit or potential harm.
- (A) STOPP (Screening Tool of Older Person's Prescription) (B) HELP (Hospital Elder Life Progress)
 (C) START (Screening Tool to Alert to Right Treatment) (D) Both A and C
40. चक्रतैलेन चाभ्यज्य सर्जचूर्णेन चूर्णयेत is mentioned as the treatment of ----- as per Sushruta.
- (A) *Kushtha* (कुष्ठ) (B) *Chippa* (चिप्प)
 (C) *Alasa* (अलस) (D) *Padadari* (पाददारि)
41. Condition in which multiple drug treatment do not give adequate control of blood pressure is termed as -----
- (A) Refractory hypertension (B) Accelerated hypertension
 (C) White coat hypertension (D) Ambulatory hypertension
42. Which of these is included as *Vayasthapana* (वयःस्थापन), as per Sushruta if taken in the *Pratah Kala* (प्रातः काल)?
- (A) उष्णोदक (B) शीतोदक
 (C) तक्र (D) शृत शीतजल
43. Which of these is the example of type III hypersensitivity reaction?
- (A) Allergic diseases (B) Acute cellular rejection
 (C) Serum sickness (D) Hyper acute transplant rejection

Kayachikitsa

44. Heat cramps is caused by -----
- (A) Intracellular sodium depletion (B) Extracellular sodium depletion
(C) Intracellular potassium depletion (D) Extracellular potassium depletion
45. What is the expanded form of LTOT?
- (A) Long term oxygen therapy (B) Long term domiciliary oxygen therapy
(C) Latest technology oxygen therapy (D) Latent domiciliary oxygen therapy
46. Which of these is **NOT** the secondary cause of polycythemia?
- (A) Myelo proliferative disorder (B) High affinity haemoglobin
(C) Lung disease (D) Cyanotic heart disease
47. Match the following in regards of pancreatic Neuro endocrine tumors
- | | |
|----------------------------|--|
| (a) Insulinoma | (i) Watery diarrhoea and hypokalaemia |
| (b) Somatostatinoma | (ii) Peptic ulcer and steatorrhoea |
| (c) ViPoma | (iii) Diabetes mellitus and steatorrhoea |
| (d) Gasterinoma | (iv) Recurrent hypoglycemia |
| (A) a-iv, b-iii, c-i, d-ii | (B) a-iv, b-i, c-ii, d-iii |
| (C) a-iii, b-iv, c-i, d-ii | (D) a-ii, b-iv, c-iii, d-i |
48. What is the actions of following cytokines in the regulation of immune response
- | | |
|---------------------------------|--|
| (a) Interlukin-1 (IL-1) | (i) Increase anti microbial and anti tumor activity of macrophage |
| (b) Interferon -gamma | (ii) Increases apoptosis and expressions of cytokines |
| (c) Interferon alpha | (iii) Stimulate neutrophil recruitment, T cell and macrophage activation |
| (d) Tumor necrosis factor alpha | (iv) Activates NK cells , CD 8+ T cells |
| (A) a-iv, b-ii, c-iii, d-i | (B) a-iii, b-ii, c-iv, d-i |
| (C) a-iii, b-i, c-iv, d-ii | (D) a-i, b-iii, c-iv, d-ii |
49. What is the characteristic feature of Alport's syndrome?
- (A) Acute renal tubular necrosis (B) Acute renal tubular inflammation
(C) Degeneration of glomerular basement membrane (D) Inflammation of glomerular basement membrane
50. Allergic bronchopulmonary aspergillosis is caused due to -----?
- (A) Aspergillus fumigates (B) Botrytis
(C) Candida albicans (D) Fusarium oxysporum

Rough Work

GENERAL INSTRUCTIONS
Ph.D. Entrance Exam 2025
Institute of Teaching and Research in Ayurveda
Jamnagar, Gujarat – 361008

1. The written Test for 100 marks is consists of MCQs of one mark each.
2. There will be 1/4th negative marking for incorrect answer.
3. The duration of the entrance test is 90 minutes i.e. 09.30 AM to 11.00 AM
4. The candidates are instructed to fill their Roll no. in the respective columns of OMR sheet and on Question booklet carefully.
5. Candidates are advised to use **black ball pen** for filling the information columns and marking answers.
6. Correct Method for marking answers is 
7. After opening the question booklet; the candidate are instructed to confirm 1 to 50 MCQs in each booklet in a sequence. Any discrepancies in this regard should immediately be reported to the Room Supervisor / Examination Center Superintendent.
8. Candidates will not be allowed with Books, Notes, Bags, Mobiles, Pagers or any other type of electronic device inside the examination center.
9. Don't mark or write anything on the question booklet except on the page given for rough work.
10. If there is any ambiguity against the question, it should be submitted to the Examination Center Superintendent before 05:00 pm on the day of examination (3rd May, 2025); **after that no such complaint will be entertained.**
11. Answer Key, Result and Merit will be displayed on <https://itra.ac.in>. No separate mark sheets or call letter for interview will be posted.
12. Decision of 'Ph.D. Admission Committee' will be final in any discrepancy.